Cargando…

Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer

The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resistance and tumor recurrence. Therefore, understandin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fong, Jason T., Jacobs, Ryan J., Moravec, David N., Uppada, Srijayaprakash B., Botting, Gregory M., Nlend, Marie, Puri, Neelu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817236/ https://www.ncbi.nlm.nih.gov/pubmed/24223799 http://dx.doi.org/10.1371/journal.pone.0078398

Ejemplares similares

Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy
por: Etnyre, Deven, et al.
Publicado: (2014)

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Botting, Gregory M., et al.
Publicado: (2015)

Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy
por: Uppada, Srijayaprakash B, et al.
Publicado: (2013)

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
por: Puri, Neelu, et al.
Publicado: (2008)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

hnRNP C1/C2 and Pur-beta proteins mediate induction of senescence by oligonucleotides homologous to the telomere overhang
por: Mulnix, Richard E, et al.
Publicado: (2013)

Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
por: Xu, Wanhong, et al.
Publicado: (2018)

EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
por: Crees, Zachary D, et al.
Publicado: (2020)

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
por: Wu, D-W, et al.
Publicado: (2016)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Knockdown of the Fat Mass and Obesity Gene Disrupts Cellular Energy Balance in a Cell-Type Specific Manner
por: Pitman, Ryan T., et al.
Publicado: (2012)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition
por: Kang, Sooyeon, et al.
Publicado: (2022)

Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
por: Simiczyjew, Aleksandra, et al.
Publicado: (2019)

Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells
por: Simiczyjew, Aleksandra, et al.
Publicado: (2023)

Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes
por: Pant, Ayush, et al.
Publicado: (2023)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Yochum, Zachary A., et al.
Publicado: (2018)

Upregulated Claudin-1 Expression Promotes Colitis-associated Cancer by promoting β-Catenin phosphorylation and activation in Notch/p-AKT Dependent Manner
por: Gowrikumar, Saiprasad, et al.
Publicado: (2019)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
por: Wilgucki, Molly, et al.
Publicado: (2022)

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Xia, Jinjing, et al.
Publicado: (2017)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts
por: Zhu, Kaibin, et al.
Publicado: (2021)

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
por: Hage, C, et al.
Publicado: (2013)

Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Fassunke, Jana, et al.
Publicado: (2018)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_24l3n0cuaafhv8cl5d79qglrl8